Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MI-676
- Development stage
- Preclinical
- Lead developer
- Charles University
- Modality
- Small Molecules
01
Overview
MI-676 is a novel, selective human constitutive androstane receptor (CAR) agonist under preclinical development for the treatment of metabolism-associated steatotic liver disease (MASLD). It acts as a hepatoprotective agent by protecting hepatocytes from palmitate-induced endoplasmic reticulum (ER) stress and lipotoxic apoptosis. Mechanistically, MI-676 suppresses SREBP-driven lipogenesis and ER stress, while concurrently activating pro-survival pathways including the GADD45B-Src-PP2A-MDM2-XIAP and CAR-AKT-MDM2 axes, ultimately leading to p53 suppression. It selectively induces CYP2B6 without transactivating CYP3A4, confirming its specificity for human CAR.
02
Targets
CXADR (Coxsackievirus and adenovirus receptor)
Beyond the preview
Go deeper on MI-676.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MI-676.